GlassScriptPhysician profile
Tami A Lee
NPI 1982665808
$2,363.21
in general payments reported to CMS, 2019-2025
28 companies · $638 in 2025
The $638 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.13 · 2022: $185 · 2023: $430 · 2024: $1,074 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $510.03 | 2022-2025 | |
| Lilly USA, LLC | $302.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $280.26 | 2022-2025 | |
| Novo Nordisk INC | $188.39 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $124.04 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $99.70 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.46 | 2024-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $86.16 | 2024 | |
| Corcept Therapeutics | $80.36 | 2025 | Korlym |
| Exact Sciences Corporation | $65.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $55.83 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Mylan Specialty L.P. | $54.04 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $50.56 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $38.53 | 2024 | |
| Sumitomo Pharma America, INC. | $37.25 | 2023-2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.52 | 2025 | Krystexxa, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.83 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $28.10 | 2025 | Fanapt |
| Insulet Corporation | $26.16 | 2023 | Omnipod |
| Abbott Laboratories | $24.28 | 2022 | |
| Medtronic, INC. | $23.76 | 2025 | Inceptiv |
| Glaxosmithkline, LLC. | $21.55 | 2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $20.67 | 2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $18.62 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.66 | 2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $16.21 | 2022 | |
| Cardiovascular Systems INC. | $15.52 | 2021 | |
| Astellas Pharma US INC | $14.44 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.